News
-
-
PRESS RELEASE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health, Inc. (NASDAQ:JAGX) granted RSUs to new employees effective October 20, 2025. RSUs vest over one year. The Company focuses on developing prescription medicines from rainforest plants for gastrointestinal distress -
-
PRESS RELEASE
Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals provides update on ongoing clinical trial for the treatment of MVID in pediatric patients, showing significant reduction in parenteral support in UAE. FDA advice sought for study advancement -
-
PRESS RELEASE
FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease
Jaguar Health announces expanded access programs for pediatric patients with microvillus inclusion disease using crofelemer powder. Positive results from initial trials presented -
-
PRESS RELEASE
Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research updates recommendation for Jaguar Health Inc to BUY with a target price of USD 35. Company reports H1/25 results in line with estimates, focuses on securing funding for promising pipeline -
-
PRESS RELEASE
Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Animal Health receives $250,000 grant from FDA's CVM for Canalevia-CA1 to treat chemotherapy-induced diarrhea in dogs. Company seeks to expand partnership for global commercialization of Canalevia
